SII inks Covax deal for 1.1 billion doses

UNICEF CHIEF SAID THE SHOTS WOULD BE DELIVERED OVER A NUMBER OF YEARS AT A COST OF ABOUT $3 PER DOSE FOR LOW- AND MIDDLE-INCOME COUNTRIES

Serum Institute will supply 1.1 billion doses of Covid-19 vaccines developed by Astrazeneca and Novavax to the Covax vaccine scheme as part of a new long-term deal, the head of the U.N. Children’s Fund said on Wednesday.

Unicef chief Henrietta Fore said the shots would be delivered over a number of years at the cost of about $3 per dose for low- and middle-income countries.

They would be produced by Serum under a technology transfer agreement, she said in a briefing.

The deal is on top of the goal of distributing 2 billion doses of vaccines to poor countries this year under the Covax facility, which is co-led by GAVI, the World Health Organization, the Coalition for Epidemic Preparedness Innovations (CEPI) and Unicef.

Unicef has also stockpiled 500 million syringes among other equipment in preparation for the roll-out of shots starting in the next few weeks, Fore said.

CEPI is working with vaccine developers to be as ready as possible to deal with changes needed to vaccines to ensure they work against more infectious Covid-19 variants that have emerged in the past few months, deputy CEO of CEPI Frederik Kristensen told the briefing.

While Serum Institute has received regulatory authorisation in India and has already supplied 11 million doses that have been paid by the Indian government, the original ‘Covid-19 Vaccine Astrazeneca’ has received authorisations in the UK, European Union, Argentina, and a few other countries.